Cambridge, United Kingdom
Bicycle Therapeutics, a clinical-stage biopharmaceutical company, is pioneering the development of Precision-Guided Therapeutics aimed at treating cancer and other diseases. Founded in 2009 and headquartered in the United Kingdom, Bicycle Therapeutics leverages Nobel Prize-winning science to innovate a new class of medicines using bicyclic peptides.
The company's proprietary Bicycle® molecules are fully synthetic short peptides with small molecule scaffolds that enhance their structural stability. This configuration allows for high affinity and selectivity in target binding, making these molecules ideal candidates for drug development. Their flagship projects include zelenectide pevedotin, targeting Nectin-4, and BT5528, targeting the historically undruggable EphA2.
With a substantial recent investment of $555.00M in May 2024, the company has attracted significant backing from prominent investors such as RA Capital Management, Deep Track Capital, and EcoR1 Capital, indicating robust confidence in its innovative pipeline and technology.
Emergence Therapeutics
